NASDAQ:ILMN - Illumina Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Illumina, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $324.72 +2.73 (+0.85 %) (As of 12/13/2019 04:00 PM ET) Add Compare Today's Range$319.57Now: $324.72▼$326.0350-Day Range$289.41MA: $309.69▼$326.5852-Week Range$263.30Now: $324.72▼$380.76Volume606,032 shsAverage Volume720,375 shsMarket Capitalization$47.73 billionP/E Ratio56.77Dividend YieldN/ABeta1.06 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Analytical instruments Sub-IndustryLife Sciences Tools & Services SectorMedical Current SymbolNASDAQ:ILMN Previous Symbol CUSIP45232710 CIK1110803 Webhttp://www.illumina.com/ Phone858-202-4500Debt Debt-to-Equity Ratio0.41 Current Ratio6.82 Quick Ratio6.15Price-To-Earnings Trailing P/E Ratio56.77 Forward P/E Ratio50.34 P/E Growth2.37 Sales & Book Value Annual Sales$3.33 billion Price / Sales14.32 Cash Flow$7.37 per share Price / Cash Flow44.05 Book Value$26.16 per share Price / Book12.41Profitability EPS (Most Recent Fiscal Year)$5.72 Net Income$826 million Net Margins28.14% Return on Equity22.05% Return on Assets12.95%Miscellaneous Employees7,300 Outstanding Shares147,000,000Market Cap$47.73 billion Next Earnings Date2/4/2020 (Estimated) OptionableOptionable Receive ILMN News and Ratings via Email Sign-up to receive the latest news and ratings for ILMN and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:ILMN Rates by TradingView Illumina (NASDAQ:ILMN) Frequently Asked Questions What is Illumina's stock symbol? Illumina trades on the NASDAQ under the ticker symbol "ILMN." How were Illumina's earnings last quarter? Illumina, Inc. (NASDAQ:ILMN) released its quarterly earnings data on Thursday, October, 24th. The life sciences company reported $1.93 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.40 by $0.53. The life sciences company earned $907 million during the quarter, compared to analysts' expectations of $872.65 million. Illumina had a net margin of 28.14% and a return on equity of 22.05%. Illumina's revenue was up 6.3% compared to the same quarter last year. During the same period last year, the business earned $1.52 earnings per share. View Illumina's Earnings History. When is Illumina's next earnings date? Illumina is scheduled to release their next quarterly earnings announcement on Tuesday, February 4th 2020. View Earnings Estimates for Illumina. What guidance has Illumina issued on next quarter's earnings? Illumina issued an update on its FY19 earnings guidance on Thursday, October, 24th. The company provided earnings per share (EPS) guidance of $6.40-6.45 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.04. What price target have analysts set for ILMN? 14 Wall Street analysts have issued 12-month price objectives for Illumina's shares. Their forecasts range from $280.00 to $380.00. On average, they expect Illumina's stock price to reach $331.85 in the next year. This suggests a possible upside of 2.2% from the stock's current price. View Analyst Price Targets for Illumina. What is the consensus analysts' recommendation for Illumina? 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 1 sell rating, 3 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Illumina. What are Wall Street analysts saying about Illumina stock? Here are some recent quotes from research analysts about Illumina stock: 1. Canaccord Genuity analysts commented, "We don’t believe an ultra-premium multiple is now justified for a company looking to grow +6% on the top and bottom lines, which now seem more vulnerable to large misses. What’s more, we lack visibility to 2020 or 2021 growth rates given a wide range of moving parts. We would look to get more constructive if our concerns prove to be transitory, or if ILMN announces the $100 genome at a price point that would meaningfully accelerate its top line and not add further headwinds to its gross, operating or net income margins. ILMN is working hard to drive down the cost of sequencing to be able to usher in the eagerly awaited $100 genome. DTC troubles. On the call, Illumina CEO Francis deSouza indicated he expects a DTC reacceleration “in the coming years,” which to us doesn’t imply a recovery in 2020." (7/30/2019) 2. According to Zacks Investment Research, "Illumina continues to register strong top line growth across the company’s high throughput, mid throughput and low throughput categories. In the last-reported fourth quarter, the company observed strong demand for sequencing and array systems, consumables and services. Meanwhile HiSeq to NovaSeq upgrade cycle is progressing well and NextSeq placements are strong. We are also looking forward to the company's newly-inked Pacific Biosciences deal. In the past year, Illumina has outperformed its industry. However, we note that, Illumina exited the fourth quarter of 2018 on a mixed note with earnings lagging the Zacks Consensus Estimate. HiSeq consumables are continuing with their expected decline. Seasonality in DTC functionality continues to dent Illumina’s microarray sales. Funding issues restrict growth. The company is operating in a tough competitive landscape." (4/2/2019) Has Illumina been receiving favorable news coverage? Media headlines about ILMN stock have trended somewhat positive this week, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Illumina earned a daily sentiment score of 1.8 on InfoTrie's scale. They also gave news headlines about the life sciences company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Illumina. Are investors shorting Illumina? Illumina saw a increase in short interest in the month of November. As of November 15th, there was short interest totalling 3,750,000 shares, an increase of 7.4% from the October 31st total of 3,490,000 shares. Based on an average trading volume of 999,400 shares, the short-interest ratio is presently 3.8 days. Currently, 2.6% of the shares of the company are sold short. View Illumina's Current Options Chain. Who are some of Illumina's key competitors? Some companies that are related to Illumina include Thermo Fisher Scientific (TMO), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), BIO-TECHNE (TECH), Bruker (BRKR), Charles River Laboratories Intl. (CRL), Cambrex (CBM), Luminex (LMNX), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO) and aTyr Pharma (LIFE). What other stocks do shareholders of Illumina own? Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Visa (V), Baidu (BIDU), Walt Disney (DIS), Adobe (ADBE), Gilead Sciences (GILD), Paypal (PYPL) and salesforce.com (CRM). Who are Illumina's key executives? Illumina's management team includes the folowing people: Mr. Jay T. Flatley, Exec. Chairman (Age 66)Mr. Francis A. deSouza, CEO, Pres & Director (Age 48)Mr. Sam A. Samad, CFO & Sr. VP (Age 49)Mr. Omead Ostadan, Sr. VP of Products, Marketing & Strategic Planning (Age 47)Ms. Aimee L. Hoyt, Chief People Officer & Sr. VP (Age 48) Who are Illumina's major shareholders? Illumina's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (0.89%), Nikko Asset Management Americas Inc. (0.51%), Massachusetts Financial Services Co. MA (0.47%), Chevy Chase Trust Holdings Inc. (0.33%), Voya Investment Management LLC (0.32%) and WCM Investment Management LLC (0.29%). Company insiders that own Illumina stock include A Blaine Bowman, Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karin Eastham, Marc Stapley, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Phillip G Febbo, Robert P Ragusa, Robert S Epstein and Sam Samad. View Institutional Ownership Trends for Illumina. Which major investors are selling Illumina stock? ILMN stock was sold by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., State of New Jersey Common Pension Fund D, Stifel Financial Corp, State of Michigan Retirement System, Robeco Institutional Asset Management B.V., Stephens Investment Management Group LLC, Castleark Management LLC and Gabelli Funds LLC. Company insiders that have sold Illumina company stock in the last year include Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karin Eastham, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Phillip G Febbo, Robert P Ragusa, Robert S Epstein and Sam Samad. View Insider Buying and Selling for Illumina. Which major investors are buying Illumina stock? ILMN stock was bought by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., California Public Employees Retirement System, Voya Investment Management LLC, Massachusetts Financial Services Co. MA, Parnassus Investments CA, Ardevora Asset Management LLP and WCM Investment Management LLC. View Insider Buying and Selling for Illumina. How do I buy shares of Illumina? Shares of ILMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Illumina's stock price today? One share of ILMN stock can currently be purchased for approximately $324.72. How big of a company is Illumina? Illumina has a market capitalization of $47.73 billion and generates $3.33 billion in revenue each year. The life sciences company earns $826 million in net income (profit) each year or $5.72 on an earnings per share basis. Illumina employs 7,300 workers across the globe.View Additional Information About Illumina. What is Illumina's official website? The official website for Illumina is http://www.illumina.com/. How can I contact Illumina? Illumina's mailing address is 5200 ILLUMINA WAY, SAN DIEGO CA, 92122. The life sciences company can be reached via phone at 858-202-4500 or via email at [email protected] MarketBeat Community Rating for Illumina (NASDAQ ILMN)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 971 (Vote Outperform)Underperform Votes: 863 (Vote Underperform)Total Votes: 1,834MarketBeat's community ratings are surveys of what our community members think about Illumina and other stocks. Vote "Outperform" if you believe ILMN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ILMN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/14/2019 by MarketBeat.com StaffFeatured Article: Are sell-side analysts objective?
